Corrigendum: The Role of Organic Synthesis in the Emergence and Development of Antibody–Drug Conjugates as Targeted Cancer Therapies

The authors noticed that the term “intrachain disulfide” is erroneously used five times within this Review (three in main text, and once Figure 6 9, respectively). In fact, disulfide bonds described are interchain disulfides. Thus, word “intrachain” should read “interchain” on page 11213, left column, line 2, 5; 11214, right 25, 1; 11231, 3. Revised versions of Figures which contain corrected wording also an adjusted depiction bridges provided below. Doxorubicin-based antibody–drug conjugate (26, BMS-182248) by Bristol-Myers Squibb Pharmaceutical Research Institute (1993). For clarity only one conjugation site shown [the drug-to-antibody ratio (DAR) for BMS-182248 was determined to be 6–8]. A) Construction Adcetris (62, brentuximab vedotin); B) liberated payload (57) after lysosomal linker cleavage. apologize inadvertent error.